Date: 2013-12-10
Type of information: R&D agreement
Compound: antibody therapeutics for the treatment of neurodegenerative diseases
Company: Antitope (UK) Annexon (USA)
Therapeutic area: Neurodegenerative diseases
Type agreement: R&D
Action mechanism:
Disease: neurodegenerative diseases
Details: * On December 10, 2013, Antitope, a PolyTherics company, has announced that it has entered a research agreement with Annexon to generate novel antibody therapeutics for the treatment of neurodegenerative diseases. Under the terms of the agreement Annexon will provide antibodies against specific components of the complement system and Antitope will use its Composite Human Antibody™ technology to generate a series of fully humanised antibodies devoid of T cell epitopes and with a consequent low risk of clinical immunogenicity. Annexon will screen the Composite Human Antibodies provided by Antitope and select a lead antibody to take forward into further preclinical and clinical studies. Annexon’s most advanced programme is for an orphan autoimmune neurological indication. The antibodies are expected to halt the progression of disease and allow the body to repair.
Financial terms:
Latest news:
